These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 32528470)

  • 21. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.
    Khononov I; Jacob E; Fremder E; Dahan N; Harel M; Raviv Z; Krastev B; Shaked Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.
    Cecil D; Park KH; Curtis B; Corulli L; Disis MN
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
    Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
    Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine.
    Albershardt TC; Parsons AJ; Reeves RS; Flynn PA; Campbell DJ; Ter Meulen J; Berglund P
    Vaccine; 2020 Apr; 38(17):3369-3377. PubMed ID: 32088020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
    Yip YL; Smith G; Koch J; Dübel S; Ward RL
    J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
    Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
    BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.
    Sun L; Li CW; Chung EM; Yang R; Kim YS; Park AH; Lai YJ; Yang Y; Wang YH; Liu J; Qiu Y; Khoo KH; Yao J; Hsu JL; Cha JH; Chan LC; Hsu JM; Lee HH; Yoo SS; Hung MC
    Cancer Res; 2020 Jun; 80(11):2298-2310. PubMed ID: 32156778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
    Saleh R; Toor SM; Al-Ali D; Sasidharan Nair V; Elkord E
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32616706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
    Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
    Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target.
    Pierini S; Tanyi JL; Simpkins F; George E; Uribe-Herranz M; Drapkin R; Burger R; Morgan MA; Facciabene A
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.
    Kotraiah V; Phares TW; Browne CD; Pannucci J; Mansour M; Noe AR; Tucker KD; Christen JM; Reed C; MacKay A; Weir GM; Rajagopalan R; Stanford MM; Chung CS; Ayala A; Huang J; Tsuji M; Gutierrez GM
    Front Immunol; 2020; 11():264. PubMed ID: 32210956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.
    Tobias J; Drinić M; Schmid A; Hladik A; Watzenböck ML; Battin C; Garner-Spitzer E; Steinberger P; Kundi M; Knapp S; Zielinski CC; Wiedermann U
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
    Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
    Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of Her-2/neu vaccine utilizing idiotypic network cascade.
    Pal S; Saha A; Mohanty K; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Cancer Biol Ther; 2007 Dec; 6(12):1916-25. PubMed ID: 18059165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.